/EINPresswire.com/ -- LIVINGSTON, NJ--(Marketwired - March 01, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced the appointment of Joseph M. Chalil, MD, MBA, FACHE to the company's Global Advisory Board, where he will aid in the commercial development and worldwide rollout of the company's medical instruments.

Dr. Chalil is a physician and executive at Boehringer Ingelheim, the world's largest privately held pharmaceutical company. Dr. Chalil is also the Chairman of Global Clinical Research and Trial Network of the American Association of Physicians of Indian Origin (AAPI), the second largest physician organization in the US, second only to the AMA, and has served as scientific advisor to AAPI for the past five years.

Dr. Chalil holds three US patents and his research includes clinical trial management in cystic fibrosis, multiple myeloma, and publications in the American Journal of Respiratory and Critical Care Medicine. He is a visiting professor at various universities and board member of various companies. Dr. Chalil is an expert in US healthcare policy and a strong advocate for patient centered care. Recent honors include:

• Recipient of the prestigious 2015 AAPI National Presidential Award
• Recipient of the 2013 Outstanding 50 Asian Americans in Business Award
• 2013 AAPI New York President's Award winner
• Honoree by the American Association of Cardiologists of Indian Origin (AACIO) for his achievements in the field of cardiology in 2013
• Boehringer Ingelheim President's Club winner for 2011 & 2014

Leonard Osser, CEO of Milestone Scientific, commented, "We welcome the involvement of Dr. Chalil as we enter the final stages of our U.S. clinical trials for the epidural instrument. Dr. Chalil brings an impressive background and a wealth of commercial and regulatory experience as a senior executive at the world's largest privately held pharmaceutical company. As a successful inventor and physician, he also brings a unique perspective from both an entrepreneurial and clinical perspective. We look forward to working closely with Dr. Chalil as we advance toward finalization of our 400 patient epidural study and then begin the full commercial rollout of our epidural instrument following regulatory marketing clearance."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020